S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda

Corcept Therapeutics (CORT) Short Interest Ratio & Short Volume

$22.95
+0.29 (+1.28%)
(As of 04/19/2024 ET)

Corcept Therapeutics Short Interest Data

Current Short Volume
21,330,000 shares
Previous Short Volume
20,220,000 shares
Change Vs. Previous Month
+5.49%
Dollar Volume Sold Short
$537.30 million
Short Interest Ratio / Days to Cover
15.0
Last Record Date
March 31, 2024
Outstanding Shares
103,520,000 shares
Float Size
89,260,000 shares
Short Percent of Float
23.90%
Today's Trading Volume
924,783 shares
Average Trading Volume
734,559 shares
Today's Volume Vs. Average
126%
cover of A Guide to High-Short-Interest Stocks and How to Trade Them ebook
Short Selling Corcept Therapeutics ?

Sign up to receive the latest short interest report for Corcept Therapeutics and its competitors with MarketBeat's FREE newsletter.

Skip Charts & View Short Interest History

CORT Short Interest Over Time

CORT Days to Cover Over Time

CORT Percentage of Float Shorted Over Time

Corcept Therapeutics Short Interest History

Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
3/31/202421,330,000 shares $537.30 million +5.5%23.9%15 $25.19
3/15/202420,220,000 shares $469.71 million +1.8%22.7%13 $23.23
2/29/202419,860,000 shares $466.71 million +1.1%22.3%13.1 $23.50
2/15/202419,640,000 shares $480.39 million +1.7%22.0%13.4 $24.46
1/31/202419,320,000 shares $407.65 million +23.3%22.0%14.4 $21.10
1/15/202415,670,000 shares $363.54 million +1.8%17.8%13.2 $23.20
12/31/202315,390,000 shares $499.87 million +0.9%17.5%17 $32.48
12/15/202315,260,000 shares $453.99 million -0.8%17.4%19.6 $29.75
11/30/202315,380,000 shares $391.73 million +0.7%17.5%21.2 $25.47
11/15/202315,270,000 shares $387.55 million +8.1%17.4%20.6 $25.38
10/31/202314,120,000 shares $396.49 million -5.6%16.1%19.4 $28.08
10/15/202314,960,000 shares $412.30 million -0.1%17.1%20 $27.56
9/30/202314,970,000 shares $407.86 million +3.4%17.1%20.8 $27.25
9/15/202314,480,000 shares $484.65 million -2.2%16.6%24.1 $33.47
8/31/202314,800,000 shares $484.40 million -0.5%17.0%23.7 $32.73
8/15/202314,870,000 shares $460.38 million -1.3%17.1%23.9 $30.96
7/31/202315,070,000 shares $383.98 million -4.2%17.3%23.9 $25.48
7/15/202315,730,000 shares $358.96 million -1.1%18.2%27.3 $22.82
6/30/202315,910,000 shares $354.00 million -5.1%18.4%25.2 $22.25
6/15/202316,770,000 shares $388.90 million +0.2%19.2%21.6 $23.19
5/31/202316,730,000 shares $392.99 million -2.3%19.2%20.9 $23.49
5/15/202317,130,000 shares $412.15 million No Change19.6%19.2 $24.06
10/31/202217,050,000 shares $487.63 million -0.8%18.3%30.1 $28.60
10/15/202217,190,000 shares $467.91 million -0.8%18.6%30.8 $27.22
9/30/202217,330,000 shares $444.34 million +1.5%18.7%29.7 $25.64
9/15/202217,070,000 shares $431.87 million -1.6%18.5%26.7 $25.30
8/31/202217,350,000 shares $447.98 million -1.0%18.8%27 $25.82
8/15/202217,530,000 shares $492.07 million -2.2%19.0%25.6 $28.07
7/31/202217,930,000 shares $513.87 million +1.1%19.0%22.4 $28.66
7/15/202217,730,000 shares $482.97 million -1.8%18.8%21.5 $27.24
6/30/202218,060,000 shares $429.47 million -0.6%17.5%20.5 $23.78
6/15/202218,170,000 shares $383.39 million -5.6%17.6%19.8 $21.10
5/31/202219,240,000 shares $400.96 million -5.2%20.4%20.1 $20.84
5/15/202220,300,000 shares $384.48 million +12.0%21.5%20.6 $18.94
4/30/202218,130,000 shares $389.98 million +9.5%19.2%18.7 $21.51
4/15/202216,560,000 shares $405.55 million +2.8%17.6%17.5 $24.49
3/31/202216,110,000 shares $362.80 million -2.8%N/A18 $22.52
3/15/202216,570,000 shares $397.68 million +2.3%17.6%16.7 $24.00
2/28/202216,200,000 shares $361.10 million -0.9%17.1%9.6 $22.29
2/15/202216,340,000 shares $331.87 million -10.2%17.2%9.5 $20.31
Now Open: Crypto emergency update (Ad)

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

CORT Short Interest - Frequently Asked Questions

What is Corcept Therapeutics' current short interest?

Short interest is the volume of Corcept Therapeutics shares that have been sold short but have not yet been closed out or covered. As of March 31st, investors have sold 21,330,000 shares of CORT short. 23.90% of Corcept Therapeutics' shares are currently sold short. Learn More on Corcept Therapeutics' current short interest.

What is a good short interest ratio for Corcept Therapeutics?

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. CORT shares currently have a short interest ratio of 15.0. Learn More on Corcept Therapeutics's short interest ratio.

Which institutional investors are shorting Corcept Therapeutics?

As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Corcept Therapeutics: Citadel Advisors LLC, Kynam Capital Management LP, and Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.

What is a good short interest percentage for Corcept Therapeutics?

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 23.90% of Corcept Therapeutics' floating shares are currently sold short.

Is Corcept Therapeutics' short interest increasing or decreasing?

Corcept Therapeutics saw a increase in short interest in March. As of March 31st, there was short interest totaling 21,330,000 shares, an increase of 5.5% from the previous total of 20,220,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

What is Corcept Therapeutics' float size?

Corcept Therapeutics currently has issued a total of 103,520,000 shares. Some of Corcept Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Corcept Therapeutics currently has a public float of 89,260,000 shares.

How does Corcept Therapeutics' short interest compare to its competitors?

23.90% of Corcept Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Corcept Therapeutics: Supernus Pharmaceuticals, Inc. (9.20%), Axsome Therapeutics, Inc. (16.15%), Taro Pharmaceutical Industries Ltd. (0.49%), Pacira BioSciences, Inc. (8.04%), Xencor, Inc. (9.72%), OPKO Health, Inc. (28.56%), Perrigo Company plc (2.85%), ADC Therapeutics SA (1.81%), Atea Pharmaceuticals, Inc. (2.26%), Jazz Pharmaceuticals plc (5.41%),

Which stocks are the most shorted right now?

As of the most recent reporting period, the following stocks had the largest short interest positions: TC Energy Co. ($4.49 billion), T-Mobile US, Inc. ($3.94 billion), General Motors ($3.34 billion), Charter Communications, Inc. ($3.32 billion), Occidental Petroleum Co. ($3.21 billion), Super Micro Computer, Inc. ($3.13 billion), Coinbase Global, Inc. ($3.08 billion), Moderna, Inc. ($2.28 billion), Tractor Supply ($2.24 billion), and Royal Caribbean Cruises Ltd. ($2.14 billion). View all of the most shorted stocks.

What does it mean to sell short Corcept Therapeutics stock?

Short selling CORT is an investing strategy that aims to generate trading profit from Corcept Therapeutics as its price is falling. CORT shares are trading up $0.29 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

How does a short squeeze work against Corcept Therapeutics?

A short squeeze for Corcept Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of CORT, which in turn drives the price of the stock up even further.

How often is Corcept Therapeutics' short interest reported?

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including CORT, twice per month. The most recent reporting period available is March, 31 2024.



More Short Interest Resources from MarketBeat

This page (NASDAQ:CORT) was last updated on 4/21/2024 by MarketBeat.com Staff

From Our Partners